Skip to content
Life Sciences Series A Founded 2017

Scailyte

Artificial intelligence (AI) based single-cell data analysis for novel biomarker discovery. Artificial intelligence (AI) based single-cell data analysis for novel biomarker discovery. The company is developing AI software for single-cell data analysis to discover novel biomarkers for the early and precise detection of a wide range of complex diseases. This AI-based single-cell technology can also be used for the…

📍 Basel, Switzerland · Genomics,

Funding snapshot

Last roundSeries A
Amount$8M
Date5 December 2023
Total raised$20M
Team size18

About

Artificial intelligence (AI) based single-cell data analysis for novel biomarker discovery. Artificial intelligence (AI) based single-cell data analysis for novel biomarker discovery. The company is developing AI software for single-cell data analysis to discover novel biomarkers for the early and precise detection of a wide range of complex diseases. This AI-based single-cell technology can also be used for the identification of relevant single-cell patterns from mass cytometry data. Founded in 2017, headquartered in Basel, Switzerland. The company operates in the Life Sciences > Genomics, Native AI > Artificial Intelligence sector. Founded in 2017 and headquartered in Basel, Switzerland and has raised $20.3 million in Series A funding. Key investors include Venturelab, Zurcher Kantonalbank, Swisscom Ventures, MassChallenge, Swisscom, HEMEX, Verve Ventures, Mirabaud.

Business model

Genomics > Genomics Research > Biomarker Discovery,

MassChallenge Batches > Switzerland > 2018 > Diamond

Team background

Company Wise > Google

Institutional investors

Venturelab Zurcher Kantonalbank Swisscom Ventures MassChallenge Swisscom HEMEX Verve Ventures Mirabaud Startup days

Latest coverage

No articles yet.

Raising like Scailyte?

Analyze your pitch deck before your next raise.

Analyze My Deck →